Background
==========

Worldwide, hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death and is the sixth most common cause of malignancy \[[@b1-medscimonit-26-e918824]\]. Due to the high rate of hepatitis B virus (HBV) infection, the number of cases of HCC diagnosed in China represent approximately 50% of total Europe and Northern America cases \[[@b2-medscimonit-26-e918824]\]. Surgical resection of the primary tumor is considered to provide good clinical outcome for patients with HCC in the early stages. However, despite significant advances in surgical techniques, the recurrence rates and mortality rates in patients with HCC after liver resection remain high. Currently, alpha-fetoprotein (AFP) is used as a serum tumor biomarker for patients with HCC and is used following surgery to monitor recurrence, but its diagnostic efficacy is unreliable \[[@b3-medscimonit-26-e918824]\]. Therefore, it is necessary to find new biomarkers to evaluate prognosis in patients with HCC following hepatic resection.

In recent decades, studies have shown that systemic inflammatory response may have a role in tumor progression \[[@b4-medscimonit-26-e918824],[@b5-medscimonit-26-e918824]\]. The prognostic role of indicators of a systemic including the monocyte-to-lymphocyte ratio (MLR), the platelet-to-lymphocyte ratio (PLR), and the neutrophil-to-lymphocyte ratio (NLR) have been demonstrated in many tumors \[[@b6-medscimonit-26-e918824]--[@b13-medscimonit-26-e918824]\]. Also, previous studies have shown that fibrinogen plays an important role in systemic inflammatory response and tumorigenesis \[[@b14-medscimonit-26-e918824]--[@b17-medscimonit-26-e918824]\]. Sun et al. showed that an increased NLR, PLR, and reduced LMR were significantly associated with cancer-specific survival (CSS), overall survival (OS) and with malignant phenotypes in patients with esophageal squamous cell carcinoma \[[@b6-medscimonit-26-e918824]\]. Ji et al. showed that increased level of plasma fibrinogen was significantly associated with poor prognosis in tumors of the gastrointestinal tract \[[@b17-medscimonit-26-e918824]\].

Recent studies have shown that the combined fibrinogen and neutrophil-to-lymphocyte ratio (F-NLR) score was a prognostic marker for outcome in patients with several tumors, including gastric cancer, non-small cell lung cancer (NSCLC), ovarian cancer, and esophageal cancer \[[@b18-medscimonit-26-e918824]--[@b22-medscimonit-26-e918824]\]. However, the prognostic role of the F-NLR score for patients with HCC remains unknown. Therefore, this retrospective study aimed to investigate the prognostic role of the combined F-NLR score in patients with resectable HCC at a single center.

Material and Methods
====================

Patients
--------

This retrospective study included 292 patients with primary hepatocellular carcinoma (HCC) who underwent liver resection at the Third Affiliated Hospital of Sun Yat-sen University between 2009 and 2015. The study was conducted according to the standards of the Helsinki Declaration and was approved by the Ethics Committee of the Third Affiliated Hospital of Sun Yat-sen University.

Study inclusion and exclusion criteria
--------------------------------------

All patients had a histologically confirmed diagnosis of primary HCC and were staged according to the Barcelona Clinic Liver Cancer (BCLC) staging system \[[@b3-medscimonit-26-e918824]\]. The Child-Pugh class was determined for the severity of liver damage, with class A (no liver damage), class B (moderate liver damage), and class C (severe liver damage). The study inclusion criteria were patients diagnosed with primary HCC, which was confirmed by two pathologists, with no other concurrent malignant tumors, and who had negative tumor margins on surgical resection. Patients included in the study also had no history of infection or inflammatory disease one month before surgery, and all patients had complete laboratory data. Study exclusion criteria included preoperative anti-inflammatory, immunosuppressive, or anti-tumor therapy, or a history of other primary malignancies.

Clinical data evaluated for patients with HCC who underwent liver resection
---------------------------------------------------------------------------

Perioperative blood transfusion was defined as the infusion of red blood cell concentrate before, during, or after surgery. Patients who were infused other blood products, such as albumin, platelets, and fresh frozen plasma were not considered to have had a transfusion. After surgical resection, patients were followed every three months for the first three years, and then for every six months. Routine laboratory tests were recorded, including liver function tests and measurement of serum alpha-fetoprotein (AFP). Imaging studies were performed for all patients and included abdominal ultrasound, and magnetic resonance imaging (MRI), or thoracoabdominal computed tomography (CT). A bone scan was performed if the recurrence of HCC was suspected.

Evaluation of the combined fibrinogen and neutrophil-to-lymphocyte ratio (F-NLR)
--------------------------------------------------------------------------------

The results of laboratory investigations performed one week before surgery were recorded from the patient medical records. Data were analyzed for alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), fibrinogen (Fb), prealbumin (PA), albumin, gamma-glutamyl transpeptidase (GGT), the neutrophil count, the platelet count, the lymphocyte count, and the monocyte count. The neutrophil count divided by the lymphocyte count was defined as the neutrophil-to-lymphocyte ratio (NLR). The platelet count, divided by the lymphocyte count, was defined as the platelet-to-lymphocyte ratio (PLR). The monocyte count divided by the lymphocyte count was defined as the monocyte-to-lymphocyte ratio (MLR).

Optimal cut-off values for fibrinogen and the NLR
-------------------------------------------------

The area under the curve (AUC) of the receiver operating characteristic (ROC) curve was used to identify the optimal cut-off value as the continuous variable with the largest Youden index. Based on the ROC curve analysis, the optimal cut-off value for fibrinogen was 3.35 g/L, the optimal cut-off value for the NLR was 2.47. The AUC for fibrinogen was 0.640, and the AUC for the NLR was 0.604.

The F-NLR score
---------------

The F-NLR scores were 2, 1, and 0. Patients with a fibrinogen level \>3.35 g/L and an increased NLR \>2.47 had an F-NLR score of 2. Patients with only one of the two criteria had an F-NLR score of 1. Patients with none of these criteria had an F-NLR score of 0.

Follow-up, disease-free survival (DFS), and overall survival (OS)
-----------------------------------------------------------------

Disease-free survival (DFS) and overall survival (OS) were the primary study outcomes. DFS was defined as the interval between the time of surgery and first tumor progression or death or date of the last follow-up. OS was defined as the interval between the time of surgery and the time of death or last follow-up.

Statistical analysis
--------------------

Data were analyzed using SPSS software version 20.0 (SPSS Inc., Chicago, IL, USA). The categorical variables were described by frequency (%). If the continuous variables satisfied a normal distribution, they were expressed as the mean±standard deviation (SD) using the 95% confidence interval (CI). If the data did not conform to a normal distribution, the median and the 25--75% quartiles were used. Differences between the F-NLR score and the clinicopathological features or laboratory parameters were evaluated using the chi-squared (χ^2^) test and the Kruskal-Wallis test, respectively. The Kaplan-Meier method and the log-rank test were used to compare the survival data between groups. Cox proportional hazard regression analysis was used to screen for independent prognostic factors for OS and DFS. Significant parameters in the univariate regression analysis were validated using multivariate analysis using a forward step-wise method. A p-value \<0.05 was considered as statistically significant.

Results
=======

Baseline characteristics of patients with resectable HCC
--------------------------------------------------------

There were 292 patients with hepatocellular carcinoma (HCC) who underwent liver resection. The study group included 141 patients (48.3%) who were \>50 years of age, and 34 female patients (11.6%). There were 258 patients (88.4%) who were positive for hepatitis B surface antigen (HBsAg), 132 patients (45.2%) had a blood transfusion, 22 patients (7.5%) had Child-Pugh class B liver function, and 85 patients (29.1%) had multiple lesions. The median age was 50 years (range, 41.3--58.8 years) at the time of diagnosis. Using the Barcelona Clinic Liver Cancer (BCLC) class, there were 21 (7.2%), 96 (32.9%), 57 (19.5%), and 118 (40.4%) patients with BCLC class 0, class A, class B, and class C, respectively. Other baseline data, including laboratory and hematological parameters, are shown in [Table 1](#t1-medscimonit-26-e918824){ref-type="table"}. The receiver operating characteristic (ROC) curves for fibrinogen and the neutrophil-to-lymphocyte ratio (NLR) for overall survival (OS) are shown in [Figure 1](#f1-medscimonit-26-e918824){ref-type="fig"}. The area under the ROC curve for fibrinogen and NLR were 0.640 and 0.604, respectively.

The associations between the clinicopathologic features and laboratory parameters and fibrinogen or NLR in patients with resectable HCC
---------------------------------------------------------------------------------------------------------------------------------------

The associations between fibrinogen or NLR and clinicopathological features in patients with HCC are shown in [Table 2](#t2-medscimonit-26-e918824){ref-type="table"}. Fibrinogen levels were significantly correlated with the presence of tumor thrombus in HCC (P=0.001), tumor diameter (P\<0.001), vascular invasion (P\<0.001), differentiation (P=0.043), and the Barcelona Clinic Liver Cancer (BCLC) class (P\<0.001). Also, the value for the NLR was significantly associated with a history of blood transfusion (P=0.009), the Child-Pugh grade (P=0.035), and tumor thrombus (P=0.048). The association between fibrinogen and NLR and the clinical and laboratory parameters in patients with HCC are shown in [Table 3](#t3-medscimonit-26-e918824){ref-type="table"}. Fibrinogen levels were significantly correlated with levels of alkaline phosphatase (ALP) (P\<0.001), fibrinogen (Fib) (P\<0.001), gamma-glutamyl transpeptidase (GGT), (P\<0.001), NLR (P\<0.001), platelet-to-lymphocyte ratio (PLR) (P\<0.001), and monocyte-to-lymphocyte ratio (MLR) (P\<0.001). Also, the value of NLR was significantly associated with ALP (P=0.005), Fib (P\<0.001), GGT (P=0.010), NLR (P\<0.001), PLR (P\<0.001), and MLR (P\<0.001).

The associations between the patient clinicopathologic features, laboratory parameters, and the combined fibrinogen and neutrophil-to-lymphocyte ratio (F-NLR) groups (scores 2, 1, and 0) in patients with resectable HCC
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The results of the associations between the three groups of F-NLR (scores 2,1, and 0) and the laboratory parameters in patients with resectable HCC are presented in [Tables 4](#t4-medscimonit-26-e918824){ref-type="table"} and [5](#t5-medscimonit-26-e918824){ref-type="table"}. In the three here were significant associations between the F-NLR and tumor thrombus (P=0.001), tumor diameter (P\<0.001), vascular invasion (P\<0.001), BCLC stage (P\<0.001), ALP (P\<0.001), Fib (P\<0.001), ALB (P=0.027), GGT (P\<0.001), NLR (P\<0.001), PLR (P\<0.001), and MLR (P\<0.001) were statistically different between the three groups of F-NLR (scores 2, 1, and 0).

Survival curve analysis of F-NLR for OS and DFS
-----------------------------------------------

The Kaplan-Meier method and log-rank test evaluated the survival differences among the three groups of F-NLR (scores 2, 1, and 0). Survival curves showed that the different scores of F-NLR distinguished between the survival curves of patients with HCC with three separate groups for OS (P\<0.001) and DFS (P\<0.001) ([Figure 2](#f2-medscimonit-26-e918824){ref-type="fig"}). Subgroup analysis of the prognostic role of the F-NLR in patients with HCC was evaluated for different tumor stages, which showed that F-NLR had a prognostic role in OS and DFS in patients with HCC, regardless of subgroups of BCLC stage ([Figure 3](#f3-medscimonit-26-e918824){ref-type="fig"}).

Univariate and multivariate analyses of OS
------------------------------------------

Univariate regression analysis showed that patient age (P=0.006), tumor thrombus (P=0.046), tumor diameter (P=0.002), AFP (P=0.013), vascular invasion (P=0.003), BCLC stage (P=0.002), ALT (P=0.045), AST (P=0.039), ALP (P=0.003), Fib (P=0.001), GGT (P=0.003), NLR (P=0.001), PLR (P=0.002), MLR (P=0.001), and F-NLR (P\<0.001) were significantly associated with OS. These variables were included in multivariate regression analysis using a forward step-wise method. The results showed that patient age (P=0.013), AFP (P=0.021), GGT (P=0.014), and F-NLR (P\<0.001) were independent factors for OS in patients with resectable HCC in this study ([Table 6](#t6-medscimonit-26-e918824){ref-type="table"}).

Univariate and multivariate analyses for DFS
--------------------------------------------

Univariate regression analysis showed that patient age (P=0.011), a history of blood transfusion (P=0.002), tumor thrombus (P\<0.001), tumor diameter (P\<0.001), tumor number (P\<0.001), AFP (P=0.023), vascular invasion (P\<0.001), BCLC stage (P\<0.001), ALT (P=0.038), AST (P=0.005), ALP (P\<0.001), Fib (P\<0.001), GGT (P=0.003), NLR (P\<0.001), PLR (P\<0.001), MLR (P\<0.001), and F-NLR (P\<0.001) were significantly associated with DFS. These variables were included in multivariate regression analysis using a forward step-wise method. The results showed that patient age (P=0.015), a history of blood transfusion (P=0.016), tumor thrombus (P=0.006), tumor number (P=0.007), ALP (P=0.010), MLR (P=0.019), and F-NLR (P=0.002) were independent factors for DFS in patients with resectable HCC in this study ([Table 7](#t7-medscimonit-26-e918824){ref-type="table"}).

Discussion
==========

Although there have been recent developments in the diagnosis and treatment of hepatocellular carcinoma (HCC), the 5-year overall survival (OS) rate of patients remains unsatisfactory \[[@b2-medscimonit-26-e918824]\]. The progression of tumors are not only determined by the biological characteristics of the tumor, but may be influenced by preoperative biochemical and hematological parameters \[[@b4-medscimonit-26-e918824],[@b5-medscimonit-26-e918824]\]. The use of appropriate prognostic indicators can provide risk stratification for patients with HCC and guidance for the choice of treatment. The aim of this retrospective study was to investigate the prognostic role of the combined fibrinogen and neutrophil-to-lymphocyte ratio (F-NLR) in patients with resectable HCC at a single center. Demographic, clinicopathological, and laboratory parameters of 292 patients with HCC were analyzed correlated with the three groups of F-NLR (scores 2, 1, and 0).

Inflammation is recognized to be associated with tumor development and progression. The inflammatory response promotes the production of inflammatory mediators in tumor cells and the tumor microenvironment that facilitate tumor cell growth, invasion, and angiogenesis \[[@b5-medscimonit-26-e918824],[@b23-medscimonit-26-e918824]\].

The neutrophil-to-lymphocyte ratio (NLR) is a marker of human cancer as lymphocytes play a significant role in immune editing and immune surveillance, and can also inhibit the invasion, migration, and proliferation of tumor cells \[[@b4-medscimonit-26-e918824]\]. Activation of T lymphocytes can destroy tumor cells and induce tumor cell apoptosis \[[@b24-medscimonit-26-e918824]\]. Increased circulating lymphocyte counts are favorable prognostic indicators in patients with HCC \[[@b24-medscimonit-26-e918824]\]. Also, circulating neutrophils can produce cytokines involved in cancer cell proliferation, migration, and proliferation, including vascular endothelial growth factor (VEGF), tumor necrosis factor-α (TNF-α), and interleukins \[[@b25-medscimonit-26-e918824],[@b26-medscimonit-26-e918824]\]. In 2017, Yuan et al. showed that an increased neutrophil count in the peripheral blood was an independent indicator of poor prognosis in patients with HCC treated with sorafenib \[[@b27-medscimonit-26-e918824]\]. Therefore, the neutrophil-to-lymphocyte ratio (NLR) has been used as a marker of the systemic inflammatory response in patients with HCC.

Hyperfibrinogenemia has also previously been shown to be associated with poor prognosis in many tumors, but the underlying mechanisms remain unclear. However, fibrinogen can facilitate the adhesion of cancer cells to platelets, leading to the formation of platelet aggregation around the cancer cells, which may prevent immune attack \[[@b28-medscimonit-26-e918824]\]. Fibrinogen can regulate the proliferation, invasion, and metastasis of tumor cells by binding to growth factors, including platelet-derived growth factor (PDGF), fibroblast growth factor-2 (FGF-2), and vascular endothelial growth factor (VEGF) \[[@b29-medscimonit-26-e918824]--[@b31-medscimonit-26-e918824]\]. Tumor progression is accompanied by an increased inflammatory response with leukocyte infiltration in the tumor matrix, which convert fibrinogen to fibrin that promotes tumor angiogenesis \[[@b25-medscimonit-26-e918824]\]. Also, studies have shown that fibrinogen can facilitate epithelial-mesenchymal transition (EMT) of cancer cells and promote invasion and metastasis \[[@b14-medscimonit-26-e918824]\]. In this study, the novel preoperative prognostic index, the F-NLR score, was studied that combines fibrinogen, neutrophil, and lymphocyte counts. The F-NLR score may reflect the preoperative inflammatory response and changes in the tumor microenvironment in HCC.

The F-NLR score has previously been shown as an independent variable in the prognosis of patients with ovarian cancer, gastric cancer, non-small cell lung cancer (NSCLC), and esophageal cancer \[[@b18-medscimonit-26-e918824]--[@b22-medscimonit-26-e918824]\]. However, studies on the prognostic significance of the F-NLR score in patients with HCC undergoing radical hepatectomy have not been conducted previously. In this retrospective study, the prognostic significance of the F-NLR score in patients with HCC following hepatic resection showed a significant correlation with tumor thrombus, larger tumor diameter, vascular invasion, and an increased Barcelona Clinic Liver Cancer (BCLC) stage, which was supported by subgroup analysis. Univariate and multivariate regression analysis showed that the F-NLR score was an independent risk factor for prognosis in patients with HCC following liver resection.

Currently, the BCLC stage is an important predictive and prognostic method for the selection of treatment options for patients with HCC \[[@b3-medscimonit-26-e918824]\]. However, the BCLC stage in HCC mainly reflects the pathological behavior of the resected tumor. The findings from the present study showed that the preoperative F-NLR score represented a new prognostic biomarker for patients with HCC which does not require additional diagnostic costs as the results of routine laboratory investigations can be used. Also, the F-NLR score can be used to supplement the BCLC stage to identify patients at high risk of recurrence or spread for HCC.

This study had several limitations. This study was retrospective and was conducted at a single-center with a small sample size. Because some inflammatory indicators were not routinely tested at our center, there was no data to analyze, including for C-reactive protein. Also, this study included patients who underwent radical hepatic resection for HCC, and the findings may not apply to patients with HCC who have unresectable primary tumors. Therefore, the findings from this retrospective study require validation with large-scale, multicenter, controlled clinical studies.

Conclusions
===========

This retrospective study aimed to investigate the prognostic role of the combined fibrinogen and neutrophil-to-lymphocyte ratio (F-NLR) in patients with resectable hepatocellular carcinoma (HCC). The combined F-NLR score, a new inflammatory indicator, was shown to be an independent predictor of prognosis in terms of overall survival (OS) and disease-free survival (DFS), according to the Barcelona Clinic Liver Cancer (BCLC) stage. Further prospective clinical studies are needed to determine whether the combined F-NLR score has a clinical role in identifying high-risk patients with HCC and whether this test can be used to benefit patients by part of the evaluation for individualized treatment.

**Source of support:** This study was supported by the Guangzhou Science and Technology Project (No. 201707010112), and the Anhui Natural Science Foundation Project (No. 1608085MH164 and No. 1608085QH182)

![Receiver operating characteristic (ROC) curve analysis of a combined fibrinogen and neutrophil-to-lymphocyte ratio (F-NLR) score and overall survival (OS) in patients with resectable hepatocellular carcinoma (HCC). (**A**) ROC curve analysis for OS and fibrinogen. (**B**) ROC curve analysis for OS and NLR. ROC -- receiver operating characteristic; NLR -- neutrophil-to-lymphocyte ratio; OS -- overall survival.](medscimonit-26-e918824_g001){#f1-medscimonit-26-e918824}

![Kaplan-Meier survival curves for overall survival (OS) and disease-free survival (DFS) using the combined fibrinogen and neutrophil-to-lymphocyte ratio (F-NLR), in patients with resectable hepatocellular carcinoma (HCC). (**A**) Kaplan-Meier survival curve for overall survival (OS) and the F-NLR. (**B**) Kaplan-Meier survival curve for disease-free survival (DFS) and the F-NLR. OS -- overall survival; DFS -- disease-free survival; F-NLR -- combined fibrinogen and neutrophil-to-lymphocyte ratio (F-NLR).](medscimonit-26-e918824_g002){#f2-medscimonit-26-e918824}

![Kaplan-Meier survival curves for overall survival (OS) and disease-free survival (DFS) using the combined fibrinogen and neutrophil-to-lymphocyte ratio (F-NLR) according to the Barcelona Clinic Liver Cancer (BCLC) stage in patients with resectable hepatocellular carcinoma (HCC). (**A, B**) Kaplan-Meier survival curve for overall survival (OS) using the F-NLR according to the Barcelona Clinic Liver Cancer (BCLC) stage. (**C, D**) Kaplan-Meier survival curve for disease-free survival (DFS) using the F-NLR according to the BCLC stage. OS -- overall survival; DFS -- disease-free survival; BCLC -- Barcelona Clinic Liver Cancer stage.](medscimonit-26-e918824_g003){#f3-medscimonit-26-e918824}

###### 

Clinical and demographic characteristics of the patients with hepatocellular carcinoma (HCC) included in this study.

  Characteristic        Patients (%)
  --------------------- -----------------------
  Age (years)           
   ≤50                  151 (51.7)
   \>50                 141 (48.3)
  Gender                
   Male                 258 (88.4)
   Female               34 (11.6)
  HBsAg                 
   Negative             34 (11.6)
   Positive             258 (88.4)
  Cirrhosis             
   No                   89 (30.5)
   Yes                  203 (69.5)
  Transfusion           
   No                   160 (54.8)
   Yes                  132 (45.2)
  Child-Pugh grade      
   A                    270 (92.5)
   B                    22 (7.5)
  Tumor thrombus        
   No                   264 (90.4)
   Yes                  28 (9.6)
  Tumor diameter (cm)   
   ≤5                   162 (55.5)
   \>5                  130 (44.5)
  Tumor number          
   Single               207 (70.9)
   Multiple             85 (29.1)
  AFP                   
   ≤400                 200 (68.5)
   \>400                92 (31.5)
  Vascular invasion     
   No                   174 (59.6)
   Yes                  118 (40.4)
  Differentiation       
   1                    52 (17.8)
   2                    219 (75.0)
   3                    21 (7.2)
  BCLC                  
   0                    21 (7.2)
   A                    96 (32.9)
   B                    57 (19.5)
   C                    118 (40.4)
  ALT (U/L)             38.0 (26.0--51.8)
  AST (U/L)             37.0 (28.0--51.8)
  ALP (U/L)             79.0 (67.0--101.0)
  Fib (g/L)             3.02 (2.45--3.67)
  PA (mg/L)             179.5 (139.3--223.0)
  ALB (g/L)             39.8±4.1
  GGT (U/L)             57.5 (36.0--112.0)
  NLR                   1.94 (1.48--2.72)
  PLR                   10.54 (72.63--135.27)
  MLR                   0.26 (0.19--0.36)

AFP -- alpha fetoprotein; BCLC -- Barcelona-Clinic Liver Cancer staging system; ALT -- alanine aminotransferase; AST -- aspartate aminotransferase; ALP -- alkaline phosphatase; Fib -- fibrinogen; PA, prealbumin; ALB -- albumin; GGT -- gamma-glutamyl transpeptidase; NLR -- neutrophil-to-lymphocyte ratio; PLR -- platelet-to-lymphocyte ratio; MLR -- monocyte-to-lymphocyte ratio.

###### 

Associations between the clinicopathological characteristics of the patients with hepatocellular carcinoma (HCC) included in this study and the fibrinogen and neutrophil-to-lymphocyte ratio (NLR).

  Variables              Fibrinogen   P-value   NLR           P-value        
  ---------------------- ------------ --------- ------------- --------- ---- -----------
  Age (years)                                   0.168                        0.525
   ≤50                   90           61                      103       48   
   \>50                  95           46                      101       40   
  Gender                                        0.862                        0.372
   Male                  163          95                      178       80   
   Female                22           12                      26        8    
  HBsAg                                         0.336                        0.274
   Negative              19           15                      21        13   
   Positive              166          92                      183       75   
  Cirrhosis                                     0.092                        0.182
   No                    50           39                      67        22   
   Yes                   135          68                      137       66   
  Transfusion                                   0.928                        **0.009**
   No                    101          59                      122       38   
   Yes                   84           48                      82        50   
  Child-Pugh grade                              0.062                        **0.035**
   A                     167          103                     193       77   
   B                     18           4                       11        11   
  Tumor thrombus                                **0.001**                    **0.048**
   No                    175          89                      189       75   
   Yes                   10           18                      15        13   
  Tumor diameter (cm):                          **\<0.001**                  0.080
   ≤5                    125          37                      120       42   
   \>5                   60           70                      84        46   
  Tumor number                                  0.446                        0.914
   Single                134          73                      145       62   
   Multiple              51           34                      59        26   
  AFP                                           0.852                        0.940
   \<400                 126          74                      140       60   
   ≥400                  59           33                      64        28   
  Vascular invasion                             **\<0.001**                  0.094
   No                    130          44                      128       46   
   Yes                   55           63                      76        42   
  Differentiation                               **0.043**                    0.187
   Well/moderate         176          95                      192       79   
   Poor                  9            12                      12        9    
  BCLC stage                                    **\<0.001**                  0.087
   0                     18           3                       18        3    
   A                     74           22                      73        23   
   B                     38           19                      37        20   
   C                     55           63                      76        42   

AFP -- alpha fetoprotein; BCLC -- Barcelona-Clinic Liver Cancer staging system.

###### 

Hematological parameters of the patients with hepatocellular carcinoma (HCC) included in this study and the fibrinogen and neutrophil-to-lymphocyte ratio (NLR).

  Variables   Fibrinogen             P-value                NLR           P-value                                       
  ----------- ---------------------- ---------------------- ------------- ---------------------- ---------------------- -------------
  ALT (U/L)   37.0 (26.0--52.0)      39.0 (29.0--53.0)      0.315         37.0 (26.0--50.8)      38.0 (30.0--59.0)      0.312
  AST (U/L)   35.0 (28.0--48.0)      40.0 (30.0--56.0)      0.096         36.0 (28.0--49.0)      39.0 (29.0--58.0)      0.122
  ALP (U/L)   73.0 (61.0--98.0)      84.0 (75.0--120.0)     **\<0.001**   77.0 (64.0--98.0)      81.0 (71.3--118.0)     **0.005**
  Fib (g/L)   2.61 (2.20--2.95)      3.89 (3.63--4.63)      **\<0.001**   2.92 (2.38--3.43)      3.51 (2.64--4.14)      **\<0.001**
  PA (mg/L)   181.0 (142.0--214.5)   177.0 (137.0--229.0)   0.948         183.5 (143.3--222.3)   169.5 (134.0--224.5)   0.383
  ALB (g/L)   39.9±4.3               39.6±3.8               0.606         40.0±4.1               39.4±4.2               0.273
  GGT (U/L)   51.0 (33.0--88.5)      77.0 (47.0--138.0)     **\<0.001**   53.5 (34.0--101.8)     72.5 (39.3--127.0)     **0.010**
  NLR         1.79 (1.35--2.41)      2.32 (1.74--3.55)      **\<0.001**   1.67 (1.25--2.02)      3.55 (2.92--4.71)      **\<0.001**
  PLR         89.4 (67.8--113.4)     129.7 (95.8--165.1)    **\<0.001**   90.2 (68.1--113.5)     133.5 (104.9--195.0)   **\<0.001**
  MLR         0.24 (0.18--0.32)      0.31 (0.22--0.44)      **\<0.001**   0.23 (0.17--0.30)      0.38 (0.29--0.52)      **\<0.001**

AFP -- alpha fetoprotein; BCLC -- Barcelona-Clinic Liver Cancer staging system; ALT -- alanine aminotransferase; AST -- aspartate aminotransferase; ALP -- alkaline phosphatase; Fib -- fibrinogen; PA -- prealbumin; ALB -- albumin; GGT -- gamma-glutamyl transpeptidase; NLR -- neutrophil-to-lymphocyte ratio; PLR -- platelet-to-lymphocyte ratio; MLR -- monocyte-to-lymphocyte ratio.

###### 

Association between the clinicopathologic features and the combined fibrinogen and neutrophil-to-lymphocyte ratio (F-NLR).

  Variables             F-NLR   P-value        
  --------------------- ------- --------- ---- -------------
  Age (years)                                  0.315
   ≤50                  68      57        26   
   \>50                 76      44        21   
  Gender                                       0.119
   Male                 128     85        45   
   Female               16      16        2    
  HBsAg                                        0.190
   Negative             12      16        6    
   Positive             132     85        41   
  Cirrhosis                                    0.241
   No                   40      37        12   
   Yes                  104     64        35   
  Transfusion                                  0.181
   No                   83      57        20   
   Yes                  61      44        27   
  Child-Pugh grade                             0.942
   A                    133     94        43   
   B                    11      7         4    
  Tumor thrombus                               **0.001**
   No                   136     92        36   
   Yes                  8       9         11   
  Tumor diameter (cm)                          **\<0.001**
   ≤5                   98      49        15   
   \>5                  46      52        32   
  Tumor number                                 0.202
   Single               107     65        35   
   Multiple             37      36        12   
  AFP                                          0.936
   \<400                99      68        33   
   ≥400                 45      33        14   
  Vascular invasion                            **\<0.001**
   No                   101     56        17   
   Yes                  43      45        30   
  Differentiation                              0.069
   Well/moderate        137     94        40   
   Poor                 7       7         7    
  BCLC stage                                   **\<0.001**
   0                    15      6         0    
   A                    60      27        9    
   B                    26      23        8    
   C                    43      45        30   

AFP -- alpha fetoprotein; BCLC -- Barcelona Clinic Liver Cancer.

###### 

Relationship between hematological parameters and the combined fibrinogen and neutrophil-to-lymphocyte ratio (F-NLR).

  Variables   F-NLR                  P-value                                        
  ----------- ---------------------- ----------------------- ---------------------- -------------
  ALT (U/L)   35.0 (25.3--49.0)      41.0 (27.0--60.5)       38.0 (31.0--46.0)      0.435
  AST (U/L)   35.0 (28.0--47.8)      37.0 (27.5--55.5)       44.0 (31.0--59.0)      0.107
  ALP (U/L)   70.0 (60.0--96.8)      80.0 (69.5--99.5)       97.0 (76.0--133.0)     **\<0.001**
  Fib (g/L)   2.62 (2.19--2.95)      3.43 (2.78--3.89)       4.13 (3.68--5.23)      **\<0.001**
  PA (mg/L)   186.0 (145.0--216.0)   172.0 (133.0--2186.0)   173.0 (138.0--232.0)   0.375
  ALB (g/L)   39.7±4.2               40.5±4.2                38.5±3.6               **0.027**
  GGT (U/L)   50.5 (32.3--91.8)      59.0 (37.0--103.0)      98.0 (56.0--175.0)     **\<0.001**
  NLR         1.60 (1.23--1.96)      2.18 (1.74--3.14)       3.69 (3.02--4.89)      **\<0.001**
  PLR         83.3 (62.4--105.3)     114.9 (91.4--146.5)     152.9 (120.2--230.9)   **\<0.001**
  MLR         0.22 (0.16--0.28)      0.29 (0.22--0.36)       0.44 (0.31--0.55)      **\<0.001**

AFP -- alpha fetoprotein; BCLC -- Barcelona-Clinic Liver Cancer staging system; ALT -- alanine aminotransferase; AST -- aspartate aminotransferase; ALP -- alkaline phosphatase; Fib -- fibrinogen; PA -- prealbumin; ALB -- albumin; GGT -- gamma-glutamyl transpeptidase; NLR -- neutrophil-to-lymphocyte ratio; PLR -- platelet-to-lymphocyte ratio; MLR -- monocyte-to-lymphocyte ratio.

###### 

Univariate and multivariate analyses of overall survival (OS).

  Variable                                     Univariate analysis   Multivariate analysis                                                
  -------------------------------------------- --------------------- ----------------------- ------------------ ------------- ----------- ------------------
  Age (years) (≤50 *vs.* \>50)                 **0.006**             **0.409**               **0.217--0.774**   **0.013**     **0.446**   **0.235--0.845**
  Gender (Female *vs.* Male)                   0.750                 0.860                   0.339--2.178                                 
  HBsAg (yes *vs.* no)                         0.225                 2.060                   0.640--6.632                                 
  Cirrhosis (yes *vs.* no)                     0.937                 0.935                   0.523--1.819                                 
  Transfusion (yes *vs.* no)                   0.514                 1.210                   0.683--2.142                                 
  Child-Pugh grade (B/A)                       0.382                 0.531                   0.129--2.191                                 
  Tumor thrombus (yes *vs.* no)                **0.046**             **2.268**               **1.015--5.070**   **--**                    
  Tumor diameter (cm) (\>5 *vs.* ≤5)           **0.002**             **2.497**               **1.397--4.466**   **--**                    
  Tumor number (multiple *vs.* single)         0.335                 1.344                   0.737--2.451                                 
  AFP (≥400 *vs.* \<400)                       **0.013**             **2.070**               **1.169--3.667**   **0.021**     **1.969**   **1.108--3.498**
  Vascular invasion (yes *vs.* no)             **0.003**             **2.350**               **1.327--4.161**   **--**                    
  Differentiation (poor *vs.* moderate/well)   0.140                 1.908                   0.809--4.496                                 
  BCLC stage (C/B/A/0)                         **0.002**             **1.656**               **1.213--2.263**   **--**                    
  ALT (\>37 *vs.* ≤37)                         **0.045**             **1.897**               **1.015--3.543**   **--**                    
  AST (\>39 *vs.* ≤39)                         **0.039**             **1.832**               **1.032--3.253**   **--**                    
  ALP (\>98 *vs.* ≤98)                         **0.003**             **2.360**               **1.327--4.196**   **--**                    
  Fib (\>3.35 *vs.* ≤3.35)                     **0.001**             **2.697**               **1.518--4.791**   **--**                    
  PA (\>168 *vs.* ≤168)                        0.654                 0.878                   0.497--1.550                                 
  ALB (\>38.9 *vs.* ≤38.9)                     0.258                 1.424                   0.772--2.628                                 
  GGT (\>64 *vs.* ≤64)                         **0.003**             **2.844**               **1.416--5.710**   **0.014**     **2.439**   **1.202--4.952**
  NLR (\>2.47 *vs.* ≤2.47)                     **0.001**             **2.624**               **1.475--4.667**   **--**                    
  PLR (\>102.53 *vs.* ≤102.53)                 **0.002**             **2.656**               **1.452--4.860**   **--**                    
  MLR (\>0.31 *vs.* ≤0.31)                     **0.001**             **2.666**               **1.491--4.767**   **--**                    
  F-NLR (2/1/0)                                **\<0.001**           **2.187**               **1.523--3.141**   **\<0.001**   **2.011**   **1.390--2.909**

OS -- overall survival; AFP -- alpha fetoprotein; BCLC -- Barcelona-Clinic Liver Cancer staging system; ALT -- alanine aminotransferase; AST -- aspartate aminotransferase; ALP -- alkaline phosphatase; Fib -- fibrinogen; PA -- prealbumin; ALB -- albumin; GGT -- gamma-glutamyl transpeptidase; NLR -- neutrophil-to-lymphocyte ratio; PLR -- platelet-to-lymphocyte ratio; MLR -- monocyte-to-lymphocyte ratio.

###### 

Univariate and multivariate analysis of disease-free survival (DFS).

  Variable                                     Univariate analysis   Multivariate analysis                                              
  -------------------------------------------- --------------------- ----------------------- ------------------ ----------- ----------- ------------------
  Age (years) (≤50 *vs.* \>50)                 **0.011**             **0.636**               **0.448--0.902**   **0.015**   **0.645**   **0.453--0.920**
  Gender (Female *vs.* Male)                   0.114                 0.594                   0.312--1.133                               
  HBsAg (yes *vs.* no)                         0.364                 1.293                   0.742--2.251                               
  Cirrhosis (yes *vs.* no)                     0.468                 0.873                   0.605--1.260                               
  Transfusion (yes *vs.* no)                   **0.002**             **1.702**               **1.207--2.398**   **0.016**   **1.536**   **1.083--2.178**
  Child-Pugh grade (B/A)                       0.957                 0.982                   0.515--1.874                               
  Tumor thrombus (yes *vs.* no)                **\<0.001**           **3.071**               **1.938--4.867**   **0.006**   **1.991**   **1.223--3.239**
  Tumor diameter (\>5 *vs.* ≤5)                **\<0.001**           **2.360**               **1.668--3.340**   **-**                   
  Tumor number (multiple *vs.* single)         **\<0.001**           **1.914**               **1.348--2.719**   **0.007**   **1.637**   **1.145--2.341**
  AFP (≥400 *vs.* \<400)                       **0.023**             **1.511**               **1.060--2.155**   **-**                   
  Vascular invasion (yes *vs.* no)             **\<0.001**           **1.915**               **1.360--2.696**   **-**                   
  Differentiation (poor *vs.* moderate/well)   0.948                 0.978                   0.496--1.925                               
  BCLC stage (C/B/A/0)                         **\<0.001**           **1.565**               **1.304--1.878**   **-**                   
  ALT (\>37 *vs.* ≤37)                         **0.038**             **1.463**               **1.022--2.093**   **-**                   
  AST (\>39 *vs.* ≤39)                         **0.005**             **1.628**               **1.156--2.294**   **-**                   
  ALP (\>98 *vs.* ≤98)                         **\<0.001**           **1.898**               **1.348--2.674**   **0.010**   **1.592**   **1.119--2.265**
  Fib (\>3.35 *vs.* ≤3.35)                     **\<0.001**           **1.957**               **1.390--2.756**   **-**                   
  PA (\>168 *vs.* ≤168)                        0.897                 0.977                   0.691--1.382                               
  ALB (\>38.9 *vs.* ≤38.9)                     0.143                 0.774                   0.548--1.091                               
  GGT (\>64 *vs.* ≤64)                         **0.003**             **1.734**               **1.198--2.508**   **-**                   
  NLR (\>2.47 *vs.* ≤2.47)                     **\<0.001**           **2.381**               **1.679--3.378**   **-**                   
  PLR (\>102.53 *vs.* ≤102.53)                 **\<0.001**           **1.935**               **1.364--2.743**   **-**                   
  MLR (\>0.31 *vs.* ≤0.31)                     **\<0.001**           **2.274**               **1.610--3.213**   **0.019**   **1.602**   **1.080--2.377**
  F-NLR (2/1/0)                                **\<0.001**           **1.899**               **1.519--2.374**   **0.002**   **1.496**   **1.161--1.929**

DFS -- disease free survival; AFP -- alpha fetoprotein; BCLC -- Barcelona-Clinic Liver Cancer staging system; ALT -- alanine aminotransferase; AST -- aspartate aminotransferase; ALP -- alkaline phosphatase; Fib -- fibrinogen; PA -- prealbumin; ALB -- albumin; GGT -- gamma-glutamyl transpeptidase; NLR -- neutrophil-to-lymphocyte ratio; PLR -- platelet-to-lymphocyte ratio; MLR -- monocyte-to-lymphocyte ratio.
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